{{Rsnum
|rsid=4970834
|Gene=CELSR2
|Chromosome=1
|position=109272258
|Orientation=plus
|GMAF=0.1667
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=CELSR2
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 62.5 | 31.2 | 6.2
| HCB | 94.8 | 5.2 | 0.0
| JPT | 88.4 | 9.8 | 1.8
| YRI | 42.4 | 46.5 | 11.1
| ASW | 64.9 | 26.3 | 8.8
| CHB | 94.8 | 5.2 | 0.0
| CHD | 94.5 | 5.5 | 0.0
| GIH | 65.3 | 31.7 | 3.0
| LWK | 53.3 | 40.2 | 6.5
| MEX | 77.6 | 22.4 | 0.0
| MKK | 61.0 | 36.4 | 2.6
| TSI | 73.5 | 23.5 | 2.9
| HapMapRevision=28
}}{{PMID|18262040|OA=1
}} [[rs599839]] and [[rs4970834]] explain about 1% of the variation in circulating LDL-cholesterol levels. "When we look at this particular genetic variance, of all the cholesterol variation among the population, 1% of it can be attributed to this particular locus," said Sandhu. "This is equivalent to more established genes for LDL regulation, particularly APOE." [[rs646776]] also linked.
{{PMID|18979498|OA=1
}} [[rs599839]], [[rs4970834]] and [[rs17228212]] associated with non-HDL [[cholesterol]]. 

{{PMID Auto
|PMID=19380133
|Title=Significant impact of chromosomal locus 1p13.3 on serum LDL cholesterol and on angiographically characterized coronary atherosclerosis
}}

{{PMID Auto
|PMID=20370913
|Title=Genome-wide association analysis of total cholesterol and high-density lipoprotein cholesterol levels using the Framingham heart study data
|OA=1
}}

{{PMID|18179892|OA=1
}} Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia.

{{PMID|19161620|OA=1
}} An open access database of genome-wide association results.

{{PMID|19951432|OA=1
}} Analysis of recently identified dyslipidemia alleles reveals two loci that contribute to risk for carotid artery disease.

{{PMID|20018038|OA=1
}} Evaluation of genetic risk scores for lipid levels using genome-wide markers in the Framingham Heart Study.

{{PMID|20442857|OA=1
}} Genome-wide association study of Lp-PLA(2) activity and mass in the Framingham Heart Study.

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}